News & Updates

Show Multimedia Only

Epilepsy risk elevated in children with congenital Zika syndrome

New research suggests that in-utero exposure to Zika virus (ZIKV) alone does not increase the risk of epilepsy in early childhood, and the risk increase is limited to children who develop congenital Zika syndrome.

Epilepsy risk elevated in children with congenital Zika syndrome

11 hours ago

Antimicrobial use rises following TNFi initiation in PsA patients

12 hours ago

A recent study has noted a temporary increase in antimicrobial use following initiation of tumour necrosis factor inhibitor (TNFi) treatment, with no significant risk in serious infections, among patients with psoriatic arthritis (PsA).

Antimicrobial use rises following TNFi initiation in PsA patients

12 hours ago

Nirsevimab cuts RSV burden in newborns

15 hours ago by

A retrospective study from Italy shows an association between nirsevimab prophylaxis and a lower risk of respiratory syncytial virus (RSV) hospitalizations and a milder disease course.

Nirsevimab cuts RSV burden in newborns

15 hours ago

Tobevibart–elebsiran combo demonstrates therapeutic potential against hepatitis D

a day ago

Patients with chronic hepatitis D virus (HDV) infection appear to respond to treatment with the combination of tobevibart plus elebsiran, according to the phase II, open-label SOLSTICE trial.

Tobevibart–elebsiran combo demonstrates therapeutic potential against hepatitis D

a day ago

RSV STOPS HERE

09 Dec 2025

Memperkenalkan AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted), vaksin RSV pertama yang disetujui oleh FDA dan satu-satunya yang mengandung adjuvan untuk memberikan perlindungan optimal dalam mencegah infeksi paru-paru dan saluran pernapasan bagian bawah akibat Respiratory Syncytial Virus (RSV) pada orang dewasa berusia 50 tahun ke atas.

RSV STOPS HERE

09 Dec 2025

Oral triterpenoid antifungal works against recurrent vulvovaginal candidiasis

07 Dec 2025 by

Treatment with the first-in-class oral nonazole, triterpenoid antifungal ibrexafungerp appears to be efficacious and well-tolerated in patients with recurrent vulvovaginal candidiasis, as shown in the phase III CANDLE study.

Oral triterpenoid antifungal works against recurrent vulvovaginal candidiasis

07 Dec 2025

Portable lab-in-tube TB screening device yields results in under an hour

06 Dec 2025 by

A handheld, battery-powered lab-in-tube assay device can deliver accurate tuberculosis (TB) diagnoses in less than an hour, according to a study.

Portable lab-in-tube TB screening device yields results in under an hour

06 Dec 2025

In-utero exposure to INSTI-based ART regimens not a hazard to infant neurodevelopment

05 Dec 2025

Infants exposed to antiretroviral treatment (ART) regimens containing integrase strand transfer inhibitors (INSTIs) in utero seem to fare as well as their nonexposed peers in terms of neurodevelopment, as reported in a study.

In-utero exposure to INSTI-based ART regimens not a hazard to infant neurodevelopment

05 Dec 2025

DTG/3TC vs B/F/TAF for HIV: Similar virologic efficacy at 96 weeks

04 Dec 2025 by

Switching to dolutegravir/lamivudine (DTG/3TC) or continuing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) showed comparable virologic efficacy through 96 weeks in adults with HIV infection, according to the DYAD observational, open-label extension (OLE) study presented at IDWeek 2025.

DTG/3TC vs B/F/TAF for HIV: Similar virologic efficacy at 96 weeks

04 Dec 2025

Original New Drug Application Approvals by US FDA (16-31 October 2025)

02 Dec 2025

New drug applications approved by US FDA as of 16-31 October 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2025)

02 Dec 2025

News & Updates

Filter by Specialty:

Specialty:

Epilepsy risk elevated in children with congenital Zika syndrome

Epilepsy risk elevated in children with congenital Zika syndrome

Antimicrobial use rises following TNFi initiation in PsA patients

Antimicrobial use rises following TNFi initiation in PsA patients

Nirsevimab cuts RSV burden in newborns

Nirsevimab cuts RSV burden in newborns

Tobevibart–elebsiran combo demonstrates therapeutic potential against hepatitis D

Tobevibart–elebsiran combo demonstrates therapeutic potential against hepatitis D

RSV STOPS HERE

RSV STOPS HERE

Oral triterpenoid antifungal works against recurrent vulvovaginal candidiasis

Oral triterpenoid antifungal works against recurrent vulvovaginal candidiasis

Portable lab-in-tube TB screening device yields results in under an hour

Portable lab-in-tube TB screening device yields results in under an hour

In-utero exposure to INSTI-based ART regimens not a hazard to infant neurodevelopment

In-utero exposure to INSTI-based ART regimens not a hazard to infant neurodevelopment

DTG/3TC vs B/F/TAF for HIV: Similar virologic efficacy at 96 weeks

DTG/3TC vs B/F/TAF for HIV: Similar virologic efficacy at 96 weeks

Original New Drug Application Approvals by US FDA (16-31 October 2025)

Original New Drug Application Approvals by US FDA (16-31 October 2025)